Renalytix AI PLC ADR (RNLX): Price and Financial Metrics
GET POWR RATINGS... FREE!
RNLX POWR Grades
- RNLX scores best on the Sentiment dimension, with a Sentiment rank ahead of 90.5% of US stocks.
- RNLX's strongest trending metric is Stability; it's been moving up over the last 177 days.
- RNLX's current lowest rank is in the Quality metric (where it is better than 6.34% of US stocks).
RNLX Stock Summary
- RNLX's price/sales ratio is 22.42; that's higher than the P/S ratio of 94.76% of US stocks.
- As for revenue growth, note that RNLX's revenue has grown 75.22% over the past 12 months; that beats the revenue growth of 90.28% of US companies in our set.
- In terms of volatility of its share price, RNLX is more volatile than 86.95% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to RENALYTIX PLC, a group of peers worth examining would be STRM, VORB, ICAD, LVOX, and ISSC.
- To check out RENALYTIX PLC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001811115.
RNLX Valuation Summary
- In comparison to the median Healthcare stock, RNLX's EV/EBIT ratio is 118.18% lower, now standing at -1.2.
- RNLX's price/sales ratio has moved NA NA over the prior 33 months.
Below are key valuation metrics over time for RNLX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RNLX | 2023-03-24 | 22.4 | 4.1 | -1.6 | -1.2 |
| RNLX | 2023-03-23 | 21.6 | 4.0 | -1.6 | -1.2 |
| RNLX | 2023-03-22 | 21.0 | 3.9 | -1.5 | -1.1 |
| RNLX | 2023-03-21 | 21.4 | 3.9 | -1.6 | -1.2 |
| RNLX | 2023-03-20 | 22.7 | 4.2 | -1.7 | -1.2 |
| RNLX | 2023-03-17 | 24.3 | 4.5 | -1.8 | -1.4 |
RNLX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RNLX has a Quality Grade of F, ranking ahead of 2.15% of graded US stocks.
- RNLX's asset turnover comes in at 0.017 -- ranking 78th of 81 Healthcare stocks.
- 500 - Internal server error
The table below shows RNLX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.017 | 0.425 | -8.200 |
| 2021-03-31 | 0.014 | 0.582 | -0.987 |
| 2020-06-30 | 0.000 | NA | 4.057 |
RNLX Stock Price Chart Interactive Chart >
RNLX Price/Volume Stats
| Current price | $2.25 | 52-week high | $8.50 |
| Prev. close | $2.32 | 52-week low | $1.05 |
| Day low | $2.18 | Volume | 20,600 |
| Day high | $2.37 | Avg. volume | 51,295 |
| 50-day MA | $2.86 | Dividend yield | N/A |
| 200-day MA | $2.28 | Market Cap | 105.50M |
Renalytix AI PLC ADR (RNLX) Company Bio
Renalytix AI Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded on March 15,2018 and is headquartered in Penarth, the United Kingdom.
Latest RNLX News From Around the Web
Below are the latest news stories about RENALYTIX PLC that investors may wish to consider to help them evaluate RNLX as an investment opportunity.
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceLONDON and SALT LAKE CITY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14-16, 2023 in Snowbird, Utah. Due to the format of this event there are no formal company presentations. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through |
Renalytix announces a c.$20.3 million private placementNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA. NEITHER THIS ANNOUNCEMENT NOR ANYTHI |
Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United StatesAward for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney diseaseLONDON and SALT LAKE CITY, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces the launch of PRIME-CKD*, a consortium of industry, academic and clinical research leaders, that aims to validate and implement in clinical practice, novel biomarker-based tests that predict response to existing drugs used by patients with chroni |
Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systemsSignificant milestone will make KidneyIntelX accessible to 960,000 veterans with chronic kidney diseaseLONDON and SALT LAKE CITY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the execution of a Co-operative Research and Development Agreement (CRADA) with the U.S. Veterans Health Administration Innovation Ecosystem (VHA IE) to install the KidneyIntelX solution inside the VA Health System’s Cloud Infrastructure and interface it with the VA Electronic H |
Renalytix Plc (NASDAQ:RNLX) Q1 2023 Earnings Call TranscriptRenalytix Plc (NASDAQ:RNLX) Q1 2023 Earnings Call Transcript November 30, 2022 Operator: Good morning and welcome to the Renalytix Conference Call to review First Quarter Fiscal 2023 Financial Results. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. As a reminder, […] |
RNLX Price Returns
| 1-mo | -34.59% |
| 3-mo | 20.32% |
| 6-mo | 75.78% |
| 1-year | -67.49% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 20.32% |
| 2022 | -88.24% |
| 2021 | -0.62% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...